Trial Profile

A Pragmatic Randomized Trial to Evaluate the Vaccine Effectiveness of Abrysvo® for Preventing RSV Hospitalizations in Adults Aged 60 Years or Above

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 10 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Respiratory syncytial virus vaccine Pfizer (Primary)
Indications Respiratory syncytial virus infections
Focus Therapeutic Use
Acronyms DAN-RSV

Most Recent Events

25 Nov 2025 Planned number of patients changed from 130000 to 690000.
25 Nov 2025 Planned End Date changed from 1 Aug 2027 to 1 Aug 2028.
25 Nov 2025 Planned primary completion date changed from 1 May 2027 to 1 May 2028.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com